Terms: = Ovarian cancer AND UBR5, EDD, 51366, ENSG00000104517, EDD1, KIAA0896, HYD, MGC57263, DD5, O95071, FLJ11310
11 results:
1. Targeting ubr5 inhibits postsurgical breast cancer lung metastases by inducing CDC73 and p53 mediated apoptosis.
Yu Z; Dong X; Song M; Xu A; He Q; Li H; Ouyang W; Chouchane L; Ma X
Int J Cancer; 2024 Feb; 154(4):723-737. PubMed ID: 37855385
[TBL] [Abstract] [Full Text] [Related]
2. Integrated multi-omic analysis of low-grade ovarian serous carcinoma collected from short and long-term survivors.
Wong KK; Bateman NW; Ng CW; Tsang YTM; Sun CS; Celestino J; Nguyen TV; Malpica A; Hillman RT; Zhang J; Futreal PA; Rojas C; Conrads KA; Hood BL; Dalgard CL; Wilkerson MD; Phippen NT; Conrads TP; Maxwell GL; Sood AK; Gershenson DM
J Transl Med; 2022 Dec; 20(1):606. PubMed ID: 36528667
[TBL] [Abstract] [Full Text] [Related]
3. Tumor derived ubr5 promotes ovarian cancer growth and metastasis through inducing immunosuppressive macrophages.
Song M; Yeku OO; Rafiq S; Purdon T; Dong X; Zhu L; Zhang T; Wang H; Yu Z; Mai J; Shen H; Nixon B; Li M; Brentjens RJ; Ma X
Nat Commun; 2020 Dec; 11(1):6298. PubMed ID: 33293516
[TBL] [Abstract] [Full Text] [Related]
4. Intracellular Dynamic Disentangling of Doxorubicin Release from Luminescent Nanogold Carriers by Fluorescence Lifetime Imaging Microscopy (FLIM) under Two-Photon Excitation.
Suarasan S; Craciun AM; Licarete E; Focsan M; Magyari K; Astilean S
ACS Appl Mater Interfaces; 2019 Feb; 11(8):7812-7822. PubMed ID: 30707545
[TBL] [Abstract] [Full Text] [Related]
5. GOLPH3 induces epithelial-mesenchymal transition via Wnt/β-catenin signaling pathway in epithelial ovarian cancer.
Sun J; Yang X; Zhang R; Liu S; Gan X; Xi X; Zhang Z; Feng Y; Sun Y
Cancer Med; 2017 Apr; 6(4):834-844. PubMed ID: 28332316
[TBL] [Abstract] [Full Text] [Related]
6. E3 Ubiquitin Ligase ubr5 Drives the Growth and Metastasis of Triple-Negative Breast cancer.
Liao L; Song M; Li X; Tang L; Zhang T; Zhang L; Pan Y; Chouchane L; Ma X
Cancer Res; 2017 Apr; 77(8):2090-2101. PubMed ID: 28330927
[TBL] [Abstract] [Full Text] [Related]
7. Downregulation of the proapoptotic protein MOAP-1 by the ubr5 ubiquitin ligase and its role in ovarian cancer resistance to cisplatin.
Matsuura K; Huang NJ; Cocce K; Zhang L; Kornbluth S
Oncogene; 2017 Mar; 36(12):1698-1706. PubMed ID: 27721409
[TBL] [Abstract] [Full Text] [Related]
8. edd enhances cell survival and cisplatin resistance and is a therapeutic target for epithelial ovarian cancer.
Bradley A; Zheng H; Ziebarth A; Sakati W; Branham-O'Connor M; Blumer JB; Liu Y; Kistner-Griffin E; Rodriguez-Aguayo C; Lopez-Berestein G; Sood AK; Landen CN; Eblen ST
Carcinogenesis; 2014 May; 35(5):1100-9. PubMed ID: 24379240
[TBL] [Abstract] [Full Text] [Related]
9. Intraperitoneal administration of novel doxorubicin loaded polymeric delivery systems against peritoneal carcinomatosis: experimental study in a murine model of ovarian cancer.
Colombo PE; Boustta M; Poujol S; Jarlier M; Bressolle F; Teulon I; Ladjemi MZ; Pinguet F; Rouanet P; Vert M
Gynecol Oncol; 2011 Sep; 122(3):632-40. PubMed ID: 21665252
[TBL] [Abstract] [Full Text] [Related]
10. The E3 ubiquitin ligase edd is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro.
O'Brien PM; Davies MJ; Scurry JP; Smith AN; Barton CA; Henderson MJ; Saunders DN; Gloss BS; Patterson KI; Clancy JL; Heinzelmann-Schwarz VA; Murali R; Scolyer RA; Zeng Y; Williams ED; Scurr L; Defazio A; Quinn DI; Watts CK; Hacker NF; Henshall SM; Sutherland RL
Br J Cancer; 2008 Mar; 98(6):1085-93. PubMed ID: 18349819
[TBL] [Abstract] [Full Text] [Related]
11. edd, the human orthologue of the hyperplastic discs tumour suppressor gene, is amplified and overexpressed in cancer.
Clancy JL; Henderson MJ; Russell AJ; Anderson DW; Bova RJ; Campbell IG; Choong DY; Macdonald GA; Mann GJ; Nolan T; Brady G; Olopade OI; Woollatt E; Davies MJ; Segara D; Hacker NF; Henshall SM; Sutherland RL; Watts CK
Oncogene; 2003 Aug; 22(32):5070-81. PubMed ID: 12902990
[TBL] [Abstract] [Full Text] [Related]
